Palvella Therapeutics (PVLA) said Tuesday the US Patent and Trademark Office has granted a fifth patent for its product candidate Qtorin 3.9% rapamycin anhydrous gel in treating microcystic lymphatic malformations.
Qtorin rapamycin has received multiple US Food and Drug Administration designations, including Breakthrough Therapy, Orphan Drug, and Fast Track, for treating microcystic LMs, and if approved, it could become the FDA-approved therapy for this rare genetic skin disease, granting seven years of orphan drug market exclusivity in the US.
Shares of Palvella Therapeutics were up 0.4% in recent Tuesday trading.
Price: 25.41, Change: -0.04, Percent Change: -0.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。